Welkom op de website van het Prinses Máxima Centrum.

Ga direct naar de inhoud of het hoofdmenu.

Kuiper Group

Roland Kuiper

Roland Kuiper obtained his PhD at the Radboud University Nijmegen in 2001 for his research on vesicular transport components in prohormone-producing cells. He then started as a postdoctoral fellow at the department of Human Genetics, where he became group leader Cancer Genomics in 2006. His research focuses on the identification of genomic aberrations in hereditary and non-hereditary malignancies. His group uses state-of-the-art workflows for next generation sequencing and a dedicated bioinformatics pipeline for data analysis. In 2009, he received an NWO (Dutch Science Foundation) VIDI award for his research on hereditary epimutations in colorectal cancer predisposition. He became principal investigator in 2012, and was appointed as associate professor in 2015. In November 2016, he moved with part of his group to the Princess Máxima Center for Pediatric Oncology where his research focuses on childhood cancer genetics and predisposition.

Research

The growing availability of genome-wide profiling and sequencing technologies revolutionizes our understanding of cancer genomes, and provides us with opportunities to better predict risks for cancer development and response. The Kuiper group aims to identify and investigate genetic aberrations and mechanisms involved in the process of cancer development in order to understand genetic predisposition and disease recurrence. Our research projects focus around two major themes:

  • Genomic aberrations associated with therapy resistance and relapse in leukemia. We perform an in-depth genomic characterization of (relapsed) acute lymphoblastic leukemia in order to improve its diagnosis, prognosis and risk stratification, and to provide novel options for (targeted) therapy.
  • Identification of genetic abnormalities associated with childhood cancer predisposition. Approximately 10% of the children diagnosed with cancer are genetically predisposed, a major fraction can be recognized by trained clinicians/clinical geneticists. A subset of these, however, is more difficult to recognize, and the involvement of genetic predisposition in childhood cancer may well be underestimated. We aim to identify genetic risk factors through the collection and genetic characterization of children with suspected forms of cancer predisposition.

Key Publications

  • Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.277.
  • Weren RDA, Ligtenberg MJL, Kets CM, de Voer RM, Verwiel ETP, Spruijt L, van Zelst-Stams WAG, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BBJ, Nagengast FM, Geurts van Kessel A, van Krieken JHJM, Kuiper RP*, and Hoogerbrugge N*. Identification of a novel adenomatous polyposis and colorectal cancer predisposing gene. Nat Genet,47:668-671 (2015); *shared last and corresponding author
  • de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede L, Kamping EJ, Verwiel ET, Hahn MM, Ariaans M, Spruijt L, van Essen T, Houge G, Schackert HK, Sheng JQ, Venselaar H, van Ravenswaaij-Arts CM, van Krieken JH, Hoogerbrugge N, Kuiper RP. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. Gastroenterology. 2013 145:544-547 (2013).
  • Jongmans MC, Verwiel ET, Heijdra Y, Vulliamy T, Kamping EJ, Hehir-Kwa JY, Bongers EM, Pfundt R, van Emst L, van Leeuwen FN, van Gassen KL, Geurts van Kessel A, Dokal I, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP. Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita. Am J Hum Genet. 90:426-433 (2012).
  • Kempers MJ*, Kuiper RP*, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, Gómez García EB, Eccles DM, Bunyan DJ, Syngal S, Stoffel EM, Culver JO, Palomares MR, Graham T, Velsher L, Papp J, Oláh E, Chan TL, Leung SY, van Kessel AG, Kiemeney LA, Hoogerbrugge N, Ligtenberg MJ. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 12:49-55 (2011).
  • Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, Geurts van Kessel A, Hoogerbrugge PM. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 24:1258-1264 (2010).

Group members

  • Roland Kuiper (PI)
  • Esmé Waanders (senior postdoc)
  • Jiangyan Yu (PhD student)
  • Željko Antiç (PhD student)
  • Simon van Reijmersdal (Technician)
  • Mirjam Belderbos (Pediatrician, clinical fellow in pediatric oncology (Princess Máxima Center) with 50% research time)
  • Marjolijn Jongmans (Clinical geneticist (Radboudumc/UMC Utrecht) with 20% research time)
  • Bioinformatician (vacancy)

Share this page on social media